Shots:
- CStone & SteinCares have partnered to commercialize sugemalimab, where SteinCares will gain its commercialization rights in 10 LATAM countries (incl. Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala, & Ecuador), & CStone will handle its supply
- As per the terms, SteinCares will handle regulatory filings & marketing of sugemalimab in exchange for upfront, regulatory & commercial milestones as well as revenue from product supply
- Additionally, CStone is anticipating deals for sugemalimab in Western Europe, Southeast Asia & Canada, with regulatory submissions for new indications ongoing
Ref: CStone & SteinCares | Image: CStone & SteinCares
Related News:- CStone Pharmaceuticals’s Cejemly (Sugemalimab) Receives the EC’s Approval to Treat Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
